A Meta-Analysis for Association of XRCC3 rs861539, MTHFR rs1801133, IL-6 rs1800795, IL-12B rs3212227, TNF-α rs1800629, and TLR9 rs352140 Polymorphisms with Susceptibility to Cervical Carcinoma.
Carcinoma
/ genetics
Case-Control Studies
DNA-Binding Proteins
/ genetics
Female
Genetic Predisposition to Disease
/ genetics
Humans
Interleukin-12 Subunit p40
/ genetics
Interleukin-6
/ genetics
Methylenetetrahydrofolate Reductase (NADPH2)
/ genetics
Odds Ratio
Polymorphism, Genetic
/ genetics
Risk Factors
Toll-Like Receptor 9
/ genetics
Tumor Necrosis Factor-alpha
/ genetics
Uterine Cervical Neoplasms
/ genetics
Cervical cancer
Gene
Meta-analysis
Polymorphism
cervical carcinoma
Journal
Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625
Informations de publication
Date de publication:
01 Nov 2021
01 Nov 2021
Historique:
received:
03
07
2021
entrez:
28
11
2021
pubmed:
29
11
2021
medline:
11
2
2022
Statut:
epublish
Résumé
In spite of substantial declines in both incidence and mortality rates in the past 50 years, cervical cancer remains one of the leading causes of cancer associated mortality among women globally. We performed this meta-analysis to explore the role of XRCC3 rs861539, MTHFR rs1801133, IL-6 rs1800795, IL-12B rs3212227, TNF-α rs1800629 and TLR9 rs352140 polymorphism with susceptibility to cervical carcinoma. The search databases include PubMed, SciELO, MedRxiv, Web of Science, Scopus, Cochrane Library, China National Knowledge Infrastructure, and China Biology Medicine disc up to 30 June 2021. The language is limited to English and Chinese. The comparison between the polymorphisms and cervical cancer was assessed using pooled odds ratio (OR) and 95% confidence interval (CI). The data are statistically analyzed by Comprehensive Meta-Analysis (CMA) 2.0 software. A total of 59 studies including seven studies with 1,112 cases and 1,233 controls on XRCC3 rs861539, 14 studies with 2,694 cases and 3349 controls MTHFR rs1801133, four studies with 1,121 cases and 1,109 controls on IL-12B rs3212227, seven studies with 1,452 cases and 2,186 controls on IL-6 rs1800795, 20 studies with 4,781 cases and 4909 controls on TNF-α rs1800629, and seven studies with 1743 cases and 2292 controls on TLR9 rs352140 were included. There was a significant association between XRCC3 RS861539, TNF-α rs1800629, and IL-6 rs1800795 polymorphisms and an increased risk of cervical carcinoma in overall population. However, the MTHFR rs1801133, IL-12B rs3212227 and TLR9 rs352140 polymorphisms were not associated. The pooled analysis showed that XRCC3 RS861539, TNF-α rs1800629, and IL-6 rs1800795 were associated with cervical carcinoma susceptibility, but not MTHFR rs1801133, IL-12B rs3212227 and TLR9 rs352140 polymorphisms.
Sections du résumé
BACKGROUND
BACKGROUND
In spite of substantial declines in both incidence and mortality rates in the past 50 years, cervical cancer remains one of the leading causes of cancer associated mortality among women globally. We performed this meta-analysis to explore the role of XRCC3 rs861539, MTHFR rs1801133, IL-6 rs1800795, IL-12B rs3212227, TNF-α rs1800629 and TLR9 rs352140 polymorphism with susceptibility to cervical carcinoma.
METHODS
METHODS
The search databases include PubMed, SciELO, MedRxiv, Web of Science, Scopus, Cochrane Library, China National Knowledge Infrastructure, and China Biology Medicine disc up to 30 June 2021. The language is limited to English and Chinese. The comparison between the polymorphisms and cervical cancer was assessed using pooled odds ratio (OR) and 95% confidence interval (CI). The data are statistically analyzed by Comprehensive Meta-Analysis (CMA) 2.0 software.
RESULTS
RESULTS
A total of 59 studies including seven studies with 1,112 cases and 1,233 controls on XRCC3 rs861539, 14 studies with 2,694 cases and 3349 controls MTHFR rs1801133, four studies with 1,121 cases and 1,109 controls on IL-12B rs3212227, seven studies with 1,452 cases and 2,186 controls on IL-6 rs1800795, 20 studies with 4,781 cases and 4909 controls on TNF-α rs1800629, and seven studies with 1743 cases and 2292 controls on TLR9 rs352140 were included. There was a significant association between XRCC3 RS861539, TNF-α rs1800629, and IL-6 rs1800795 polymorphisms and an increased risk of cervical carcinoma in overall population. However, the MTHFR rs1801133, IL-12B rs3212227 and TLR9 rs352140 polymorphisms were not associated.
CONCLUSION
CONCLUSIONS
The pooled analysis showed that XRCC3 RS861539, TNF-α rs1800629, and IL-6 rs1800795 were associated with cervical carcinoma susceptibility, but not MTHFR rs1801133, IL-12B rs3212227 and TLR9 rs352140 polymorphisms.
Identifiants
pubmed: 34837895
doi: 10.31557/APJCP.2021.22.11.3419
pmc: PMC9068191
pii:
doi:
Substances chimiques
DNA-Binding Proteins
0
IL12B protein, human
0
IL6 protein, human
0
Interleukin-12 Subunit p40
0
Interleukin-6
0
TLR9 protein, human
0
Toll-Like Receptor 9
0
Tumor Necrosis Factor-alpha
0
X-ray repair cross complementing protein 3
0
MTHFR protein, human
EC 1.5.1.20
Methylenetetrahydrofolate Reductase (NADPH2)
EC 1.5.1.20
Types de publication
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
3419-3431Références
Tumour Biol. 2014 Mar;35(3):2561-4
pubmed: 24197984
J Gastrointest Cancer. 2021 Mar;52(1):80-84
pubmed: 33001376
Arch Gynecol Obstet. 2016 Nov;294(6):1305-1310
pubmed: 27535759
J Infect Dis. 2005 Mar 15;191(6):969-76
pubmed: 15717274
J Clin Virol. 2012 Jan;53(1):54-9
pubmed: 22019249
Pathol Oncol Res. 2017 Apr;23(2):385-392
pubmed: 27722983
BMC Cancer. 2006 Jan 26;6:24
pubmed: 16438713
J Int Med Res. 2013 Aug;41(4):1027-36
pubmed: 23816930
Front Microbiol. 2020 Jan 21;10:3116
pubmed: 32038557
Onkologie. 2011;34(8-9):422-6
pubmed: 21934341
J Minim Invasive Gynecol. 2008 Mar-Apr;15(2):205-8
pubmed: 18312992
Clin Chem. 2002 Aug;48(8):1218-24
pubmed: 12142377
Pathol Oncol Res. 2020 Jan;26(1):307-315
pubmed: 30215163
Gynecol Oncol. 2011 Jun 1;121(3):537-41
pubmed: 21376376
Int J Immunogenet. 2020 Dec;47(6):522-528
pubmed: 32662227
J Gastrointest Cancer. 2021 Mar;52(1):73-79
pubmed: 32997314
Cancer Lett. 2001 May 10;166(1):41-6
pubmed: 11295285
Mol Biol Rep. 2011 Oct;38(7):4715-21
pubmed: 21132533
Biomarkers. 2010 Feb;15(1):61-8
pubmed: 19793004
Int Immunopharmacol. 2020 Nov;88:106925
pubmed: 32871478
Cancer Genet. 2021 Jun;254-255:11-17
pubmed: 33515810
Oncotarget. 2016 Jul 5;7(27):42216-42224
pubmed: 27285765
Int J Gynecol Cancer. 2011 Dec;21(9):1664-71
pubmed: 21897271
PLoS One. 2012;7(9):e45246
pubmed: 23028877
Int J Biol Markers. 2009 Jan-Mar;24(1):11-6
pubmed: 19404917
Pathol Oncol Res. 2012 Oct;18(4):997-1002
pubmed: 22614250
Cancer Lett. 2003 Mar 10;191(2):187-91
pubmed: 12618332
Int J Gynecol Cancer. 2017 Nov;27(9):1949-1956
pubmed: 28906311
Mol Biol Rep. 2021 Feb;48(2):1433-1437
pubmed: 33555528
Clin Biochem. 2011 Jun;44(8-9):596-600
pubmed: 21349258
Biomol Concepts. 2020 Apr 15;11(1):97-101
pubmed: 32304293
Rev Invest Clin. 2006 Sep-Oct;58(5):462-9
pubmed: 17408107
J Hum Nutr Diet. 2017 Jun;30(3):275-283
pubmed: 28466507
Mol Genet Genomic Med. 2020 Jan;8(1):e1055
pubmed: 31750632
Drug Metab Lett. 2008 Jan;2(1):18-22
pubmed: 19356065
Asian Pac J Cancer Prev. 2010;11(2):537-8
pubmed: 20843147
Eur J Obstet Gynecol Reprod Biol. 2011 Oct;158(2):330-3
pubmed: 21719187
Br J Biomed Sci. 2019 Jul;76(3):117-121
pubmed: 30870085
Int J Gynecol Cancer. 2006 May-Jun;16(3):1278-82
pubmed: 16803517
Oncotarget. 2017 May 2;8(18):29795-29807
pubmed: 28415696
J Cancer Res Clin Oncol. 2017 Dec;143(12):2437-2445
pubmed: 28819773
Pathobiology. 2008;75(6):356-63
pubmed: 19096231
Int J Gynecol Cancer. 2003 Mar-Apr;13(2):148-53
pubmed: 12657115
Mol Biol Rep. 2012 Aug;39(8):8425-30
pubmed: 22714906
Mamm Genome. 2017 Jun;28(5-6):213-219
pubmed: 28497211
Hum Genet. 2005 Mar;116(4):247-54
pubmed: 15635481
Biosci Rep. 2018 Sep 13;38(5):
pubmed: 30135142
Iran J Reprod Med. 2014 Nov;12(11):765-70
pubmed: 25709632
Mem Inst Oswaldo Cruz. 2016 Nov;111(11):663-669
pubmed: 27783717
Gynecol Oncol. 2010 Mar;116(3):544-8
pubmed: 19959217
Int J Cancer. 2006 Nov 1;119(9):2173-8
pubmed: 16804901
Arch Acad Emerg Med. 2019 Nov 10;7(1):e62
pubmed: 31875216
Mol Diagn Ther. 2015 Feb;19(1):53-7
pubmed: 25614219
Mol Biol Rep. 2012 Jul;39(7):7627-34
pubmed: 22327783
Gynecol Oncol. 2003 Mar;88(3):326-32
pubmed: 12648582
Asian Pac J Cancer Prev. 2012;13(12):6101-4
pubmed: 23464412
Biomed Rep. 2021 Jul;15(1):60
pubmed: 34094536
Front Genet. 2013 May 02;4:70
pubmed: 23675381
Asian Pac J Cancer Prev. 2018 Jun 25;19(6):1601-1606
pubmed: 29936785
Tumour Biol. 2012 Oct;33(5):1549-56
pubmed: 22592655
Eur J Obstet Gynecol Reprod Biol. 2008 Sep;140(1):71-5
pubmed: 18367309
Pathol Oncol Res. 2013 Jul;19(3):553-8
pubmed: 23539294
Cell Oncol. 2007;29(3):249-56
pubmed: 17452777
Hum Genet. 2013 Mar;132(3):301-12
pubmed: 23180271
Lancet Glob Health. 2020 Feb;8(2):e191-e203
pubmed: 31812369
J Gastrointest Cancer. 2021 Jun;52(2):389-398
pubmed: 33025423
Int J Clin Exp Med. 2015 Apr 15;8(4):5317-22
pubmed: 26131107
Arch Gynecol Obstet. 2008 Dec;278(6):517-24
pubmed: 18351371
Sci Rep. 2019 Jul 5;9(1):9729
pubmed: 31278284
Int J Cancer. 2019 May 1;144(9):2206-2214
pubmed: 30515767
Cancer Causes Control. 2011 Jan;22(1):63-72
pubmed: 21052817
Gynecol Oncol. 2004 Dec;95(3):557-63
pubmed: 15581963
Biochem Biophys Res Commun. 2005 Aug 26;334(2):588-92
pubmed: 16009345
Int J Gynecol Cancer. 2009 Oct;19(7):1190-4
pubmed: 19823053
Oncol Lett. 2020 Apr;19(4):3316-3332
pubmed: 32256826
Clin Cancer Res. 2009 Jan 1;15(1):400-5
pubmed: 19118071
J Diabetes Metab Disord. 2020 Nov 03;19(2):2005-2016
pubmed: 33520873
BMJ Case Rep. 2012 Sep 24;2012:
pubmed: 23008373
Pathol Oncol Res. 2015 Apr;21(2):339-45
pubmed: 25113639
J Obstet Gynaecol India. 2020 Dec;70(6):503-509
pubmed: 33406167
Gynecol Oncol. 2005 Jan;96(1):173-80
pubmed: 15589597
Acta Medica (Hradec Kralove). 2020;63(1):31-42
pubmed: 32422114
PLoS Genet. 2017 Aug 14;13(8):e1006866
pubmed: 28806749
Sci Rep. 2018 May 8;8(1):7244
pubmed: 29740106
BMC Med Genet. 2019 Jun 6;20(1):100
pubmed: 31170928
Asian Pac J Cancer Prev. 2011;12(4):963-6
pubmed: 21790234
Avicenna J Med Biotechnol. 2018 Jan-Mar;10(1):29-33
pubmed: 29296264
J Biomed Res. 2011 May;25(3):155-64
pubmed: 23554684
Clin Exp Obstet Gynecol. 2013;40(3):421-4
pubmed: 24283179
Pathol Oncol Res. 2016 Apr;22(2):323-30
pubmed: 26548749